<DOC>
	<DOCNO>NCT00001045</DOCNO>
	<brief_summary>To validate alteration codon 215 reverse transcriptase plasma virus precedes increase viral burden measure peripheral blood decline CD4 count observe association clinical failure zidovudine ( AZT ) . To determine whether alternative regimen antiretroviral agent alter course viral burden measure peripheral blood CD4 change patient HIV infection . To obtain data safety immunologic virologic response AZT/didanosine/nevirapine . Of HIV-1 mutation report associated zidovudine resistance , mutation codon 215 reverse transcriptase gene commonly occur great impact susceptibility . When mutation appear , change drug may prevent immunologic virologic deterioration .</brief_summary>
	<brief_title>Comparison Three Anti-HIV Drug Combinations HIV-Infected Patients With No Symptoms Disease</brief_title>
	<detailed_description>Of HIV-1 mutation report associated zidovudine resistance , mutation codon 215 reverse transcriptase gene commonly occur great impact susceptibility . When mutation appear , change drug may prevent immunologic virologic deterioration . Initially , patient receive AZT alone . After detection 215 mutation plasma RNA , patient randomize one three treatment arm : AZT alone , AZT plus ddI , AZT/ddI plus nevirapine . Patients follow every 8 week receive treatment 4 year . AS PER AMENDMENT 5/9/96 : All AZT monotherapy option eliminate . Patients randomize either Arm II Arm III , regardless codon 215 status . All patient randomize Arm I follow mutation codon 215 rerandomized Arm II Arm III . All patient randomize either Arm II Arm III follow mutation codon 215 remain initial randomized assignment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia . Antibiotics , antifungal , antiviral medication , clinically indicate . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , medication deem appropriate primary care provider . Concurrent Treatment : Allowed : Limited localized radiation therapy skin . Prior Medication : Required : AZT ( minimum 300 mg/day ) least 1 month ( uninterrupted ) 2 year immediately prior study entry . Patients must : Asymptomatic HIV infection . CD4 count 300600 cells/mm3 . No plasma/serum PCR codon 215 mutation screening . Prior AZT monotherapy . NOTE : All Department Defense ( DOD ) eligible patient must least 18 year age . Enrollment woman encourage . AS PER AMENDMENT 04/03/95 : DOD female patient must negative pregnancy test within 48 hour prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Symptomatic grade 2 bad peripheral neuropathy . Unable swallow capsule tablet . Other medical condition contraindicates study participation . Concurrent Medication : Excluded : Systemic cytotoxic chemotherapy . Biologic response modifier ( interferon , ampligen , PEGIL2 ) . AntiHIV agent study drug . Other investigational agent . Foscarnet unless clinically indicate unresponsive herpes virus infection . Chronic antacid H2 blocker use . Rifampin rifamycin class agent . Antibiotics contain clavulanic acid . Concurrent Treatment : Excluded : Radiation therapy limit localized therapy skin . Patients follow prior condition exclude : History pancreatitis . Prior Medication : Excluded : Prior therapy nucleoside nonnucleoside antiretroviral agent AZT . Immune modulate therapy ( e.g. , IFNalpha , gp160 ) within 60 day prior screen . Prior Treatment : Excluded : Blood transfusion within precede 2 week . Illicit drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>